Watch Live

Tweet TWEET

Regulatory Wins, Leadership Changes, and New Partnerships Creating Healthy Prospects - Research Report on Gilead, Biogen Idec,

  Regulatory Wins, Leadership Changes, and New Partnerships Creating Healthy
     Prospects - Research Report on Gilead, Biogen Idec, GlaxoSmithKline,
                           Viropharma, and Celsion

PR Newswire

NEW YORK, May 31, 2013

NEW YORK, May 31, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Wall Street Reports announced new research reports highlighting Gilead
Sciences, Inc. (NASDAQ: GILD), Biogen Idec Inc. (NASDAQ: BIIB),
GlaxoSmithKline plc. (ADR) (NYSE: GSK), Viropharma Inc. (NASDAQ: VPHM), and
Celsion Corporation (NASDAQ: CLSN). Today's readers may access these reports
free of charge - including full price targets, industry analysis and analyst
ratings - via the links below.

Gilead Sciences, Inc. Research Report

On May 28, 2013, Gilead Sciences, Inc. (Gilead) announced that the European
Commission has granted marketing authorization for Stribild (elvitegravir 150
mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil (as fumarate)
245 mg), a single tablet regimen for HIV-1 infection in adults who are
antiretroviral treatment-naïve or infected with HIV-1 without known mutations
associated with resistance to any of the three antiretroviral agents in
Stribild. Jürgen Rockstroh, MD, Professor of Medicine, University of Bonn,
Germany and a Lead Investigator for one of the Stribild pivotal studies,
commented, "Single tablet regimens make it easier for HIV patients to take
their treatment consistently every day, which may improve their health
outcomes. Stribild is a highly effective and well tolerated HIV treatment
regimen, and is an important addition to the growing arsenal of simplified
therapies in Europe." This approval allows the Company to market Stribild in
all 27 countries of the European Union. Stribild is the third single tablet
HIV regimen developed by the Company to become available in Europe, after
Atripla and Eviplera. Stribild is also approved in the United States, Canada,
Australia, South Korea, Japan, and Turkey. The Full Research Report on Gilead
Sciences, Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/9696_GILD]

Biogen Idec Inc. Research Report

On May 23, 2013, Biogen Idec Inc. (Biogen Idec) announced the appointment of
Spyros Artavanis-Tsakonas, Ph.D., as the Company's Chief Scientific Officer
(CSO). Dr. Artavanis-Tsakonas previously served as the Company's Chief
Scientific Officer on an interim basis while on sabbatical from Harvard
Medical School. He will now resume his role in a permanent capacity, and will
also lead the Company's research strategy, capabilities, and discovery
platforms. Doug Williams, Biogen Idec's Executive Vice President of Research
and Development, said, "He will continue what he has successfully started at
Biogen Idec-attracting and encouraging exceptional scientific talent,
enhancing our existing early discovery programs, establishing extensive
academic collaborations and leading our drug discovery strategy." The Full
Research Report on Biogen Idec Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.wsreports.com/r/full_research_report/b35f_BIIB]

GlaxoSmithKline plc. (ADR) Research Report

On May 22, 2013, GlaxoSmithKline plc. (ADR) (GSK) and the Biomedical Advanced
Research and Development Authority (BARDA), a segment of the U.S. Department
of Health and Human Services (HHS), announced a first-of-its-kind
collaboration that will support the development of several antibiotics to
fight antibiotic resistance and bioterrorism. Under the terms of the
agreement, HHS will provide $40 million for the initial 18-month agreement and
up to $200 million if the agreement is renewed over five years. According to
the GSK, this collaboration provides flexibility to move around GSK's
antibacterial portfolio, rather than focusing on just one drug candidate and
allow medicines to be studied for the potential treatment of both conventional
and biothreat pathogens. The Full Research Report on GlaxoSmithKline plc.
(ADR) - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/2737_GSK]

Viropharma Inc. Research Report

On May 28, 2013, Viropharma, Inc. (Viropharma) announced results of data
analyses from the randomized, placebo-controlled, and open label clinical
trials of Cinryze (C1 esterase inhibitor [human]). The results showed the
effectiveness of Cinryze in prevention of angioedema attacks in patients with
Hereditary Angioedema (HAE). Dr. Zuraw, Professor of Medicine, Chief of
Section of Allergy and Immunology, and Director of the Allergy and Immunology
Training Program at the University of California, said, "While clinical trials
have demonstrated the efficacy and safety of Cinryze for the long-term
prevention of HAE, these data demonstrate that Cinryze is an important option,
even in patients who have been managed on anabolic androgens and continue to
experience multiple attacks of HAE." The Full Research Report on Viropharma
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/cf37_VPHM]

Celsion Corporation Research Report

On May 22, 2013, Celsion Corporation (Celsion) announced that its proprietary
patent application, "Method of Storing Nanoparticle Formulations," has been
granted in China, Japan, South Korea, and Taiwan, the four largest markets for
liver cancer in the world. The Company holds an exclusive agreement with Duke
University for its temperature sensitive liposome technology which covers the
ThermoDox formulation. These newly issued patents pertain to methods of
storing stabilized, temperature-sensitive liposomal formulations, and will
assist in the protection of global rights by extending the overall term of the
ThermoDox patent portfolio to August 2026. The Full Research Report on Celsion
Corporation - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/ebef_CLSN]

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    making mistakes. If you notice any errors or omissions, please notify us
    below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquires, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

SOURCE Wall Street Source

Contact: WSReports.com, Phone #: +1-310-496-8071
 
Press spacebar to pause and continue. Press esc to stop.